SAGE Therapeutics (SAGE) has provided an update.
Sage Therapeutics has announced promising topline results from the Phase 2 PRECEDENT study, exploring the effectiveness of Dalzanemdor (SAGE-718) for treating Mild Cognitive Impairment in Parkinson’s Disease. This news, shared in a recent press release, could signal a significant advancement for patients and has been eagerly anticipated by the stock market and investors monitoring progress in the biotech sector.
For detailed information about SAGE stock, go to TipRanks’ Stock Analysis page.
